Evidence map›Paper›PMID 40248456›Full record

ArticleJTO clinical and research reports2025

Trends in Mesothelioma Mortality in the United States Between 1999 and 2020.

Alexander J Didier, Mingjia Li, Jinesh Gheeya, Asrar Alahmadi, Jacob Kaufman, Regan Memmott, Kai He, Peter Shields, David P Carbone, Carolyn Presley and 2 more

Abstract read
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alexander J DidierDepartment of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
Mingjia LiDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
Jinesh GheeyaDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
Asrar AlahmadiDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
Jacob KaufmanDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
Regan MemmottDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
Kai HeDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
Peter ShieldsDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
David P CarboneDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
Carolyn PresleyDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
Dwight OwenDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.
Logan RoofDivision of Medical Oncology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Mesothelioma is a rare but aggressive cancer primarily caused by asbestos exposure. In March 2024, the Environmental Protection Agency banned asbestos in the United States, but its use will take years to phase out. Therefore, asbestos remains a threat, and incidence may remain stable or slowly decrease due to the long latency between exposure and diagnosis. This study investigates mesothelioma mortality trends in the United States from 1999 to 2020, focusing on demographic and geographic variations. Methods: Data on mesothelioma-related deaths from 1999 to 2020 were extracted from the Centers for Disease Control and Prevention database. Variables including race/ethnicity, sex, geographic density, and mesothelioma subtype were assessed. Age-adjusted mortality rates were calculated per 1 million individuals and standardized to the 2000 United States population. Joinpoint regression identified statistically significant changes in mortality trends over time. Results: From 1999 to 2020, there were 54,905 mesothelioma-related deaths in the United States (age-adjusted mortality rate = 7.5). Pleural mesothelioma accounted for 8.1% of deaths, peritoneal for 4.6%, pericardial for 0.01%, other sites for 10.9%, and unspecified sites for 76.3%. Most deaths (81.3%) occurred in individuals aged over 65 years. Overall mortality decreased from 8.5 in 1999 to 5.7 in 2020 at -1.9% annually. Non-Hispanic Whites had the highest mortality, and male individuals experienced higher mortality than female individuals. Suburban and rural populations had the highest mortality rates. Conclusions: The study highlights significant declines in mesothelioma mortality in the United States from 1999 to 2020, with variations across demographic and geographic groups. Continued monitoring and targeted interventions are necessary to address disparities and further reduce mesothelioma mortality.

Indexed as

DisparitiesEpidemiologyMesotheliomaMortalityRural

Identifiers

PMID40248456
PMCPMC12005915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.